Repare Therapeutics, Inc.

BridgeBio Oncology Therapeutics (BBOT), the cancer drug company spun out of rare disease-focused BridgeBio Pharma in May 2024 with $200m in venture capital financing, announced on 28 February that it

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

BioMarin Pharmaceutical Inc. followed up its recent announcement of a shift in research and development priorities and a new commercial strategy for its hemophilia A gene therapy Roctavian (valoctoco

Two new venture capital funds based outside of the US together offer $365m for life science start-ups, including Amplitude Ventures’ second fund and XGEN Venture’s inaugural fund. Montreal-based Ampli